Tracking the impact of translational research in psychiatry: state of the art and perspectives

被引:28
作者
Machado-Vieira, Rodrigo [1 ]
机构
[1] Univ Sao Paulo, Inst & Dept Psychiat, Neurosci Lab, LIM27, Sao Paulo, Brazil
来源
JOURNAL OF TRANSLATIONAL MEDICINE | 2012年 / 10卷
关键词
Translational; Psychiatry; Personalized; Treatment; Human; Animal; Research; Biomarker; SURROGATE END-POINTS; DRUG DISCOVERY; ANIMAL-MODELS; MEDICINE; ANTIDEPRESSANT; BIOMARKERS; DISORDER; PHARMACOGENOMICS; SCHIZOPHRENIA; VALIDATION;
D O I
10.1186/1479-5876-10-175
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Personalized treatments have become a primary goal in translational psychiatric research. They include the identification of neural circuits associated with psychiatric disorders and definition of treatment according to individual characteristics. Many new tools and technologies have been developed but further efforts are required to provide clues on how these scientific advances in psychiatry may be translated into more effective therapeutic approaches. Obstacles to the progress of translational psychiatry also involve numerous scientific, financial, ethical, logistics and regulatory aspects. Also, the goal of DSM-5 to expand "signs and symptoms" classification to incorporate biological measures may help the development of new multifactorial and dimensional models able to better understand the pathophysiology of psychiatric disorders and develop improved treatments. Finally, a better understanding on the significant response variability, cognitive functioning, role of comorbidities and treatment-resistant cases are critical for the development of prevention and intervention strategies that are more effective.
引用
收藏
页数:7
相关论文
共 31 条
[1]   New Antidepressant Drugs: Beyond Monoaminergic Mechanisms [J].
Alamo, Cecilio ;
Lopez-Munoz, Francisco .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (14) :1559-1562
[2]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[3]   New approaches to antidepressant drug discovery: beyond monoamines [J].
Berton, O ;
Nestler, EJ .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (02) :137-151
[4]   Developing drugs for cognitive impairment in schizophrenia [J].
Breier, A .
SCHIZOPHRENIA BULLETIN, 2005, 31 (04) :816-822
[5]   Translational research: Crossing the valley of death [J].
Butler, Declan .
NATURE, 2008, 453 (7197) :840-842
[6]  
Cooksey D., 2006, REV UK HLTH RES FUND
[7]   Validation of experimental medicine methods in psychiatry: The P1 vital approach and experience [J].
Dawson, Gerard R. ;
Craig, Kevin J. ;
Dourish, Colin T. .
BIOCHEMICAL PHARMACOLOGY, 2011, 81 (12) :1435-1441
[8]   Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop [J].
De Gruttola, VG ;
Clax, P ;
DeMets, DL ;
Downing, GJ ;
Ellenberg, SS ;
Friedman, L ;
Gail, MH ;
Prentice, R ;
Wittes, J ;
Zeger, SL .
CONTROLLED CLINICAL TRIALS, 2001, 22 (05) :485-502
[10]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491